AMO Pharma Announces Completion of Treatment of Last Patient in Pivotal REACH-CDM Clinical Trial in Myotonic Dystrophy

AMO Pharma Limited announced completion of treatment for the final patient enrolled in the company’s REACH-CDM clinical study of the investigational therapy AMO-02.